Initial Patient Characteristics Associated With Ineligibility for Second‐Line Therapy After Progression on First‐Line Osimertinib in EGFR‐Mutated Non‐Small Cell Lung Cancer

ABSTRACT Background Osimertinib, an irreversible third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), improves survival in patients with EGFR‐mutated non‐small‐cell lung cancer (NSCLC). However, a substantial proportion of patients do not proceed to subsequent ther...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya, Haruki Kobayashi, Kazushige Wakuda, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-11-01
coleção:	Thoracic Cancer
Assuntos:	CNS metastasis EGFR‐TKI NSCLC older patients osimertinib
Acesso em linha:	https://doi.org/10.1111/1759-7714.70192
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!